Company: MDCXW
Filing Date: 2025-08-12
Form Type: 253G2
Source: 0001062993-25-014090
Chunk: 16

Company: Medicus Pharma Ltd.
Filing Date: 2025-08-12
Form: 253G2
Chunk 16
---
 weighted average grant date fair value of awards for options granted during the six months ended June 30, 2025 was $1.96. The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted average assumptions for the options granted:

|                        |   |    June 30, 2025 |
|:-----------------------|:--|-----------------:|
|                        |   | Weighted-average |
| Exercise price         | $ |             2.60 |
| Share price            | $ |             2.60 |
| Dividend               |   |                - |
| Risk-free interest     |   |            4.02% |
| Estimated life (years) |   |             5.00 |
| Expected volatility    |   |           97.36% |

For the three and six months ended June 30, 2025, stock-based compensation expense was $117,448 and $229,725, respectively. For the three and six months ended June 30, 2024, stock-based compensation expense was $585,442 and $621,395, respectively. Stock-based compensation expense has been reported in the Company's condensed consolidated statements of operations and comprehensive loss within general and administrative expenses.

7. Net loss per share Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:

|                                                                      |   | Three months ended June 30, 
                        2025 |   |   |       2024 |   |   | Six months ended June 30, 
                      2025 |   |   |       2024 |   |
|:---------------------------------------------------------------------|:--|----------------------------:|:--|:--|-----------:|:--|:--|--------------------------:|:--|:--|-----------:|:--|
| Net loss attributable to shareholders                                | $ |                  (6,176,084 | ) | $ | (3,632,859 | ) | $ |               (11,278,492 | ) | $ | (5,340,217 | ) |
| Weighted average number of common shares outstanding during the year |   |                  14,284,261 |   |   |  8,167,993 |   |   |                13,853,305 |   |   |  8,122,333 |   |
| Basic and diluted net loss per share attributable to shareholders    | $ |